Meeting
2014 ASCO Annual Meeting
Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients.
Authors
Bertrand F. Tombal
Service d'Urologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Bertrand F. Tombal , Michael Borre , Per Rathenborg , Patrick Werbrouck , Hendrik Van Poppel , Axel Heidenreich , Peter Iversen , Johan Braeckman , Jiri Heracek , Edwina Baskin-Bey , Taoufik Ouatas , Frank Perabo , De Phung , Mohammad Hirmand , Matthew Raymond Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01302041
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 5068)
DOI
10.1200/jco.2014.32.15_suppl.5068
Abstract #
5068
Poster Bd #
197
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients.
First Author: Bertrand Tombal
Poster
2018 Genitourinary Cancers Symposium
Phase II study of enzalutamide monotherapy with radiation therapy for intermediate risk prostate cancer.
First Author: Glenn Bubley
Poster
2018 Genitourinary Cancers Symposium
Phase II randomized study of abiraterone acetate plus ADT versus apalutamide versus abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels. (LACOG 0415).
First Author: Fernando C. Maluf
Poster
2024 ASCO Genitourinary Cancers Symposium
ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR).
First Author: Andrew Leonard Laccetti